Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122

Prostate cancer (PCa) is a common aggressive disease worldwide which usually progresses into incurable castration-resistant prostate cancer (CRPC) in most cases after 18–24 months treatment. Androgen receptor (AR) has been considered as a crucial factor involved in CRPC and the study of AR as a pote...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Cong, Xiaonan, He, Yundong, Wu, Haigang, Wang, Dingxiang, Liu, Yongrui, Shao, Ting, Liu, Mingyao, Yi, Zhengfang, Zheng, Jianghua, Peng, Shihong, Ding, Tao
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8210671/
https://ncbi.nlm.nih.gov/pubmed/34150618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.650919
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados